Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features

Brain metastases (BM) are one the most lethal and poorly managed clinical complications in cancer patients. These secondary tumors represent the most common intracranial neoplasm in adults, most frequently originating from lung cancer, breast cancer, and cutaneous melanoma. In primary brain tumors, such as gliomas, recent advances in DNA methylation profiling have allowed for a comprehensive molecular classification. Such data provide prognostic information, in addition to helping predict patient response to specific systemic therapies. However, epigenetic alterations of metastatic brain tumors with specific biological and translational relevance still require much further exploration. Using the widely employed Illumina Infinium HumanMethylation 450K platform, we have generated a cohort of genome-wide DNA methylomes from ninety-six needle-dissected BM specimens from patients with lung cancer, breast cancer, and cutaneous melanoma with clinical, pathological, and demographic annotations. This resource offers an unprecedented and unique opportunity to identify novel DNA methylation features influencing the behavior of brain metastasis, and thus accelerate the discovery of BM-specific theranostic epigenetic alterations.

[1]  L. Deangelis,et al.  Treatment of Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Tothill,et al.  Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[3]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[4]  Laurens van der Maaten,et al.  Accelerating t-SNE using tree-based algorithms , 2014, J. Mach. Learn. Res..

[5]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[7]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[9]  P. Laird,et al.  Low-level processing of Illumina Infinium DNA Methylation BeadArrays , 2013, Nucleic acids research.

[10]  Andrew E. Teschendorff,et al.  ChAMP: 450k Chip Analysis Methylation Pipeline , 2014, Bioinform..

[11]  D. Morton,et al.  Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome , 2015, Pigment cell & melanoma research.

[12]  J. Hainfellner,et al.  Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers , 2016, ESMO Open.

[13]  J. Wilmott,et al.  DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. , 2014, Neuro-oncology.

[14]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[15]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[16]  Neal P. Kawas,et al.  Multi-platform genome-wide analysis of melanoma progression to brain metastasis , 2014, Genomics data.

[17]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[18]  I. Shmulevich,et al.  Epigenetic profiling for the molecular classification of metastatic brain tumors , 2018, Nature Communications.

[19]  S. Chmura,et al.  Treatment of Brain Metastases , 2014, Oncology.

[20]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[21]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[22]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[23]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[24]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[25]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[26]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[28]  L. Collette,et al.  A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  I. Shmulevich,et al.  Epigenetic pro fi ling for the molecular classi fi cation of metastatic brain tumors , 2019 .

[30]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[32]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[33]  Neal P. Kawas,et al.  Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. , 2014, Human molecular genetics.